anaerobic dopamine (A-dopamine) / InBrain Pharma - LARVOL DELTA

A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson's disease symptoms. (PubMed, J Parkinsons Dis) - "Monotherapy with A-dopamine produced greater benefits than those of adjunctive therapy added to optimized oral treatment. It is interesting to note that A-dopamine and L-dopa had a different clinical effect, since no dyskinesia or psychic excitation was observed with A-dopamine, unlike with L-dopa."

Journal • Monotherapy • CNS Disorders • Dystonia • Movement Disorders • Pain • Parkinson's Disease

DIVE-FOLLOW UP: Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) (clinicaltrials.gov) - P1/2 | N=1 | Completed | Sponsor: University Hospital, Lille | Recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

DIVE-FOLLOW UP: Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) (clinicaltrials.gov) - P1/2 | N=1 | Recruiting | Sponsor: University Hospital, Lille

New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference (GlobeNewswire) - "These long-term results confirm the excellent safety profile of the continuous intracerebroventricular infusion of A-dopamine in advanced parkinsonians refractory to L-dopa and also show a sustainable effect on motor control over time."

P1/2 data • Parkinson's Disease